JP2025513502A - 液体組成物 - Google Patents

液体組成物 Download PDF

Info

Publication number
JP2025513502A
JP2025513502A JP2024562212A JP2024562212A JP2025513502A JP 2025513502 A JP2025513502 A JP 2025513502A JP 2024562212 A JP2024562212 A JP 2024562212A JP 2024562212 A JP2024562212 A JP 2024562212A JP 2025513502 A JP2025513502 A JP 2025513502A
Authority
JP
Japan
Prior art keywords
aqueous composition
pharma
acceptable salt
rilpivirine
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513502A5 (cg-RX-API-DMAC7.html
Inventor
ヴェッキ,シモーネ
コロンボ,ミリアム
サーガー,アン ギルバート ピー デ
ポール エム ヴァーストラーテン,マキシム
キャロライン エフ ヴァーヴールト,イワン
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2025513502A publication Critical patent/JP2025513502A/ja
Publication of JP2025513502A5 publication Critical patent/JP2025513502A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024562212A 2022-04-22 2023-04-24 液体組成物 Pending JP2025513502A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333556P 2022-04-22 2022-04-22
US63/333,556 2022-04-22
EP22173922 2022-05-17
EP22173922.0 2022-05-17
PCT/EP2023/060689 WO2023203258A1 (en) 2022-04-22 2023-04-24 Liquid compositions

Publications (2)

Publication Number Publication Date
JP2025513502A true JP2025513502A (ja) 2025-04-24
JP2025513502A5 JP2025513502A5 (cg-RX-API-DMAC7.html) 2026-05-08

Family

ID=86316741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562212A Pending JP2025513502A (ja) 2022-04-22 2023-04-24 液体組成物

Country Status (7)

Country Link
US (1) US20250268896A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511003A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513502A (cg-RX-API-DMAC7.html)
CN (1) CN119403543A (cg-RX-API-DMAC7.html)
CA (1) CA3249515A1 (cg-RX-API-DMAC7.html)
TW (1) TW202408516A (cg-RX-API-DMAC7.html)
WO (1) WO2023203258A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
WO2009128917A2 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
AU2020344675B2 (en) * 2019-09-13 2026-06-25 Halozyme Hypercon, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2022109555A1 (en) 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection

Also Published As

Publication number Publication date
EP4511003A1 (en) 2025-02-26
CN119403543A (zh) 2025-02-07
WO2023203258A1 (en) 2023-10-26
CA3249515A1 (en) 2023-10-26
US20250268896A1 (en) 2025-08-28
TW202408516A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
ES2317319T3 (es) Emulsiones oftalmicas que contienen un agente inmunosupresor.
DK2040671T3 (en) AURAL SUSPENSIONS OF TMC278
JP2009507925A (ja) ナノ粒子タダラフィル製剤
JP2006508105A (ja) ナノ粒子状フィブラート製剤
KR20090015994A (ko) 나노입자형 포사코나졸 제제
EP4178540A1 (en) Long-acting formulations
US20250268896A1 (en) Liquid compositions
US20250275967A1 (en) Freeze dried compositions
Sigfridsson et al. A Practical Guide for the Preparation of Drug Nanosuspensions for Preclinical Studies: Including In Vivo Case Studies
JP2023549837A (ja) 疾患又は障害の治療又は予防
TW202333725A (zh) 溶出測試
CN118251210A (zh) 溶出测试
HK40113410A (en) Dissolution test
KR101811314B1 (ko) Hiv 감염의 치료 및 예방
WO2023222754A1 (en) Rilpivirine for use in the treatment or prevention of hiv infection
WO2024068693A1 (en) Long-acting formulations
AU2016219555B2 (en) Aqueous suspensions of TMC278
CN116437923A (zh) Hiv感染的治疗或预防
EP4593834A1 (en) Long-acting formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260424